Recommendations

ACC - www.acc.org
AHA - www.americanheart.org
SCAI - www.scai.org
Smith et al. 2005
ACC/AHA/SCAI Practice Guidelines
87
Table 31. Randomized Clinical Trials of Brachytherapy for In-Stent Restenosis
Follow-Up,
n Angiographic/ Restenosis,
Trial (Ref.) Year XRT/Placebo Clinical Source XRT/Placebo
TLR, % MI, Death,
XRT/Placebo XRT/Placebo XRT/Placebo
SCRIPPS (117) 1997 26/29 6 mo Gamma 17%/54%
12 mo IR-192 (P equals 0.01)
12%/45% 4%/0% 0%/3 %
(P equals 0.01) (P equals NS) (P equals NS)
PREVENT (660) 2000 80/25 6 mo Beta 22%/50%
12 mo P-32 (P equals 0.018)
6%/24% 10%/4% 1%/0%
(P less than 0.05) (P equals NS) (P equals NS)
WRIST (116) 2000 65/65 6 mo Gamma 22%/60%
12 mo IR-192 (P equals 0.0001)
GAMMA-ONE (658) 2001 131/121 6 mo Gamma 32%/55%
9 mo IR-192 (P equals 0.01)
3%/63% 9%/9% 6%/6%
(P less than 0.001) (P equals NS) (P equals NS)
24%/42% 9.9%/4.1% 3.1%/0.8%
(P less than 0.01) (P equals 0.09) (P equals 0.17)
INHIBIT (659) 2002 166/166 9 mo Beta 26%/52%
290 d P-32 (P less than 0.0001)
8%/26% 3%/3% 3%/2%
(P less than 0.0001) (P equals NS) (P equals NS)
SCRIPPS (901) 2002 26/29 5 y Gamma NA
IR-192
23%/48% 4%/10% 19%/31%
(P equals 0.05) (P equals NS) (P equals NS)
START (92) 2002 244/232 8 mo Beta 29%/45%
Sr-90/Y-90 (P equals 0.001)
14%/25% 1.7%/3.3% 1.3%/0.5%
(P less than 0.001) (P equals 0.364) (P equals 0.625)
SVG-WRIST (902) 2002 60/60 6 mo Gamma 21%/44%
12 mo IR-192 (P equals 0.005)
17%/57% 2%/3% 7%/7%
(P less than 0.001) (P equals NS) (P equals NS)
Long WRIST (903) 2003 60/60 6 mo Gamma 45%/73%
12 mo IR-192 (P less than 0.05)
39%/62% 16.9%/18.3% 6.8%/1.7%
(P less than 0.05) (P equals NS) (P equals NS)
n indicates number of patients; NA, not applicable; NS, not significant; MI, myocardial infarction; TLR, target-lesion revascularization; and XRT, radiation therapy.